211 related articles for article (PubMed ID: 32290440)
81. Regulation of ALT-associated homology-directed repair by polyADP-ribosylation.
Hoang SM; Kaminski N; Bhargava R; Barroso-González J; Lynskey ML; García-Expósito L; Roncaioli JL; Wondisford AR; Wallace CT; Watkins SC; James DI; Waddell ID; Ogilvie D; Smith KM; da Veiga Leprevost F; Mellacharevu D; Nesvizhskii AI; Li J; Ray-Gallet D; Sobol RW; Almouzni G; O'Sullivan RJ
Nat Struct Mol Biol; 2020 Dec; 27(12):1152-1164. PubMed ID: 33046907
[TBL] [Abstract][Full Text] [Related]
82. Precision Medicine for
Principe DR
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205643
[TBL] [Abstract][Full Text] [Related]
83. ALT-FISH quantifies alternative lengthening of telomeres activity by imaging of single-stranded repeats.
Frank L; Rademacher A; Mücke N; Tirier SM; Koeleman E; Knotz C; Schumacher S; Stainczyk SA; Westermann F; Fröhling S; Chudasama P; Rippe K
Nucleic Acids Res; 2022 Jun; 50(11):e61. PubMed ID: 35188570
[TBL] [Abstract][Full Text] [Related]
84. RETRACTED: A subset of PARP inhibitors induces lethal telomere fusion in ALT-dependent tumor cells.
Mukherjee J; Pandita A; Kamalakar C; Johannessen TC; Ohba S; Tang Y; Dalle-Ore CL; Bjerkvig R; Pieper RO
Sci Transl Med; 2021 May; 13(592):. PubMed ID: 33952676
[TBL] [Abstract][Full Text] [Related]
85. The PARP Enzyme Family and the Hallmarks of Cancer Part 1. Cell Intrinsic Hallmarks.
Demény MA; Virág L
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922595
[TBL] [Abstract][Full Text] [Related]
86. Alternative lengthening of telomeres is a self-perpetuating process in ALT-associated PML bodies.
Zhang JM; Genois MM; Ouyang J; Lan L; Zou L
Mol Cell; 2021 Mar; 81(5):1027-1042.e4. PubMed ID: 33453166
[TBL] [Abstract][Full Text] [Related]
87. Oligonucleotides and microRNAs Targeting Telomerase Subunits in Cancer Therapy.
Eckburg A; Dein J; Berei J; Schrank Z; Puri N
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32825005
[TBL] [Abstract][Full Text] [Related]
88. ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms.
Southgate HED; Chen L; Tweddle DA; Curtin NJ
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32354033
[No Abstract] [Full Text] [Related]
89. Structural Motifs at the Telomeres and Their Role in Regulatory Pathways.
Alanazi AFR; Parkinson GN; Haider S
Biochemistry; 2024 Apr; 63(7):827-842. PubMed ID: 38481135
[TBL] [Abstract][Full Text] [Related]
90. Alternative lengthening of telomeres (ALT) cells viability is dependent on C-rich telomeric RNAs.
Rosso I; Jones-Weinert C; Rossiello F; Cabrini M; Brambillasca S; Munoz-Sagredo L; Lavagnino Z; Martini E; Tedone E; Garre' M; Aguado J; Parazzoli D; Mione M; Shay JW; Mercurio C; d'Adda di Fagagna F
Nat Commun; 2023 Nov; 14(1):7086. PubMed ID: 37925537
[TBL] [Abstract][Full Text] [Related]
91. Drug repositioning strategy for the identification of novel telomere-damaging agents: A role for NAMPT inhibitors.
Rizzo A; Maresca C; D'Angelo C; Porru M; Di Vito S; Salvati E; Sacconi A; Berardinelli F; Sgura A; Kuznetsov S; Potdar S; Hassinen A; Stoppacciaro A; Zizza P; Biroccio A
Aging Cell; 2023 Nov; 22(11):e13944. PubMed ID: 37858982
[TBL] [Abstract][Full Text] [Related]
92. MiR-182-3p targets TRF2 and impairs tumor growth of triple-negative breast cancer.
Dinami R; Pompili L; Petti E; Porru M; D'Angelo C; Di Vito S; Rizzo A; Campani V; De Rosa G; Bruna A; Serra V; Mano M; Giacca M; Leonetti C; Ciliberto G; Tarsounas M; Stoppacciaro A; Schoeftner S; Biroccio A
EMBO Mol Med; 2023 Jan; 15(1):e16033. PubMed ID: 36426578
[TBL] [Abstract][Full Text] [Related]
93. Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.
Gao J; Pickett HA
Nat Rev Cancer; 2022 Sep; 22(9):515-532. PubMed ID: 35790854
[TBL] [Abstract][Full Text] [Related]
94. Telomere as a Therapeutic Target in Dedifferentiated Liposarcoma.
Alessandrini I; Percio S; Naghshineh E; Zuco V; Stacchiotti S; Gronchi A; Pasquali S; Zaffaroni N; Folini M
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681604
[TBL] [Abstract][Full Text] [Related]
95. RAD51AP1 and RAD54L Can Underpin Two Distinct RAD51-Dependent Routes of DNA Damage Repair
Selemenakis P; Sharma N; Uhrig ME; Katz J; Kwon Y; Sung P; Wiese C
Front Cell Dev Biol; 2022; 10():866601. PubMed ID: 35652094
[TBL] [Abstract][Full Text] [Related]
96. CRISPR Cas13-Based Tools to Track and Manipulate Endogenous Telomeric Repeat-Containing RNAs in Live Cells.
Xu M; Chigumira T; Chen Z; Tones J; Zhao R; Dahl KN; Chenoweth DM; Zhang H
Front Mol Biosci; 2021; 8():785160. PubMed ID: 35174207
[TBL] [Abstract][Full Text] [Related]
97. To Join or Not to Join: Decision Points Along the Pathway to Double-Strand Break Repair vs. Chromosome End Protection.
Ackerson SM; Romney C; Schuck PL; Stewart JA
Front Cell Dev Biol; 2021; 9():708763. PubMed ID: 34322492
[TBL] [Abstract][Full Text] [Related]
98. High-Resolution Cartography of the Transcriptome and Methylome Landscapes of Diffuse Gliomas.
Willscher E; Hopp L; Kreuz M; Schmidt M; Hakobyan S; Arakelyan A; Hentschel B; Jones DTW; Pfister SM; Loeffler M; Loeffler-Wirth H; Binder H
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206856
[TBL] [Abstract][Full Text] [Related]
99. Telomere Maintenance Pathway Activity Analysis Enables Tissue- and Gene-Level Inferences.
Nersisyan L; Simonyan A; Binder H; Arakelyan A
Front Genet; 2021; 12():662464. PubMed ID: 33897770
[TBL] [Abstract][Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
